01. GASTRO-INTESTINAL SYSTEM
01.01 Dyspepsia and Gastro-oesophageal Reflux Disease
01.01.01 Antacids and Simeticone
01.01.02 Compound alginates and proprietary indigestion preparations
01.02 Antispasmodics and other drugs altering gut motility
01.03 Ulcer-Healing Drugs
01.03.01 H2-receptor antagonists
Medicine |
Pharmaceutical form type |
Composition |
Observation |
ranitidine
|
Injection |
25 mg/mL (as hydrochloride) in 2-mL ampoule
|
|
ranitidine
|
Syrup |
150 mg/ 10 ml
|
|
ranitidine
|
Tablet |
150 mg
|
|
01.03.02 Proton Pump Inhibitors
01.04 Acute diarrhoea
01.04.01 Antimotility drugs
01.05 Chronic bowel disorders
01.06 Laxatives
01.06.01 Bulk-Forming Laxatives
Medicine |
Pharmaceutical form type |
Composition |
Observation |
Ispaghula husk
|
Powder |
N/A
|
|
01.06.02 Stimulant Laxatives
01.06.03 Faecal Softeners
Medicine |
Pharmaceutical form type |
Composition |
Observation |
paraffin
|
Oral solution |
N/A
|
|
01.06.04 Osmotic Laxatives
01.06.05 Bowel Cleansing Solutions
01.07 Local preparations for anal and rectal disorders
01.07.01 Soothing haemorrhoidal preparations
01.07.02 Compound haemorrhoidal preparations with corticosteroids
Medicine |
Pharmaceutical form type |
Composition |
Observation |
Ultraproct
|
Ointment |
(1g contains Flucortolone Pivalate 0.92mg, Flucortolone Hexanoate 0.95mg, Cinchocaine Hydrochloride 5mg)
|
|
Ultraproct
|
Suppository |
( Flucortolone Pivalate 0.63mg, Flucortolone Hexanoate 0.610mg, Cinchocaine Hydrochloride 1mg)
|
|
01.07.03 Rectal sclerosants
Medicine |
Pharmaceutical form type |
Composition |
Observation |
oily phenol
|
Injection |
5%
|
|
01.07.04 Management of anal fissures
Medicine |
Pharmaceutical form type |
Composition |
Observation |
diltiazem
|
Cream |
2 %
|
|
01.08 Drugs affecting intestinal secretions
01.08.01 Drugs affecting biliary composition and flow
01.08.02 Bile acid sequestrants
Medicine |
Pharmaceutical form type |
Composition |
Observation |
colestiramina
|
Sachet |
4 g
|
|
01.08.03 Pancreatin
Medicine |
Pharmaceutical form type |
Composition |
Observation |
pancreatin
|
Capsule |
N/A
|
|
02. CARDIOVASCULAR SYSTEM
02.01 Cardiac Glycosides
Medicine |
Pharmaceutical form type |
Composition |
Observation |
digoxin
|
Injection |
250 micrograms/mL in 2-mL ampoule
|
|
digoxin
|
Oral liquid |
50 micrograms/mL
|
|
digoxin
|
Tablet |
0.125 mg
|
|
digoxin
|
Tablet |
250 mcg
|
|
digoxin
|
Tablet |
62.5 mcg
|
|
02.02 Diuretics
02.02.01 Thiazides and related diuretics
02.02.02 Loop diuretics
Medicine |
Pharmaceutical form type |
Composition |
Observation |
furosemide
|
Injection |
10 mg/ml
|
|
furosemide
|
Injection |
10 mg/mL in 2-mL ampoule
|
|
furosemide
|
Tablet |
40 mg
|
|
02.02.03 Potassium-sparing diuretics and aldosterone antagonists
Medicine |
Pharmaceutical form type |
Composition |
Observation |
spironolactone
|
Tablet |
25 mg
|
|
02.02.04 Potassium-sparing and Thiazide combination diuretics
02.02.05 Osmotic diuretics
Medicine |
Pharmaceutical form type |
Composition |
Observation |
mannitol
|
Parenteral solution |
20% (500 ml)
|
|
02.03 Anti-arrhythmic drugs
02.04 Beta-Adrenoceptor Blocking Drugs
02.05 Hypertension and Heart Failure
02.05.01 Vasodilator Antihypertensive Drugs
02.05.02 Centrally Acting Antihypertensive Drugs
02.05.03 Alpha-Adrenoceptor Blocking Drugs
02.05.04 Drugs affecting the Renin-angiotensin system
02.05.04.01 Angiotensin-Converting Enzyme Inhibitors